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SUBCUTANEOUS IMMUNIZATION AGAINST Leishmania major - INFECTION IN MICE: EFFICACY OF 
FORMALIN-KILLED PROMASTIGOTES COMBINED WITH ADJUVANTS
Joshua M. MUTISO(1), John C. MACHARIA(1), Rosemary M. MUTISYA(2) & Evans TARACHA(1)
SUMMARY 
Formalin-killed promastigotes (FKP) of Leishmania major, in combination with Montanide ISA 720 (MISA), BCG or alum were 
used in vaccination of an inbred murine model against cutaneous leishmaniasis (CL). Significant and specific increases in anti-FKP 
IgG responses were detected for both alum-FKP and BCG-FKP compared to MISA-FKP (p < 0.001). Significant increases in splenic 
lymphocyte recall proliferation was obtained in the MISA-FKP vaccinated mice compared to alum-FKP or BCG-FKP vaccinated 
groups (p < 0.01). The highest interferon-γ responses were observed in the BCG-FKP group followed by the MISA-FKP while the 
alum-FKP gave the least responses. Significantly reduced lesion sizes were obtained in the MISA-FKP group compared to the BCG/
alum adjuvants-FKP vaccinated groups. Although the BCG-FKP group showed the highest IFN-γ responses, it failed to control 
cutaneous lesions. Significant reductions in parasite numbers were observed in the MISA-FKP and BCG-FKP vaccinated groups (p 
< 0.001). There was a good correlation between parasite burden and IFN-γ level indicating IFN-γ response as a sensitive parameter 
of the immune status. In conclusion, MISA-FKP is the most efficacious vaccine formulation against murine cutaneous leishmaniasis.
KEYWORDS: Cutaneous leishmaniasis; Formalin-killed promastigotes (FKP) promastigotes; Montanide ISA 720 (MISA); BCG; 
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INTRODUCTION
Leishmaniasis remains a major health problem, due to inefficiency 
of available control measures. To date, there is no vaccine against any 
form of leishmaniasis for general human use (KHAMESIPOUR et 
al., 2006). Current control measures rely on chemotherapy to alleviate 
disease and on vector control to reduce transmission. Protection from 
CL has been achieved through artificial infection, a technique called 
‘leishmanization’ (GUIRGES, 1971). However, the use of live vaccines 
has had many problems including the development of large uncontrolled 
skin lesions, exacerbation of psoriasis and other skin diseases, and even 
immunosuppression (SEREBRYAKOV et al., 1972; MODABBER, 
1975). Leishmania replicates intracellularly in macrophages, and effective 
control requires macrophage activation and nitric oxide (NO)-mediated 
killing in response to Th 1- produced cytokine IFN-γ (SCOTT et al., 1988; 
STACEY & BLACKWELL, 1999). Killed antigens that could be safer 
as vaccines generally require an adjuvant for induction of a strong Th1 
immune response in murine models (KENNEY et al., 1999). 
Formalin-killed promastigotes have been used in several studies 
as antigens in vaccine candidates against leishmaniasis (HOLBROOK 
et al., 1981; COOK & HOLBROOK, 1983; HOLBROOK & COOK, 
1983). The availability of hundreds of different adjuvants has prompted 
a need for identifying rational standards for selection of adjuvant 
formulations based on safety and sound immunological principles for 
human vaccines (ALVING, 2002). The number of adjuvants currently 
approved for use in humans is quite limited and of those adjuvants that 
have been tested in humans, alum has had the greatest clinical use and 
is relatively nonreactogenic (KASLOW et al., 1994). Alum is currently 
the only Food and Drug Administration-approved adjuvant in clinical use 
in humans (TONUI et al., 2004). Aluminium salts are inexpensive, safe 
and simple to formulate (BOMFORD, 1989). Alum has been previously 
used in leishmania candidate vaccines alone or in combination with 
other adjuvants (KENNEY et al., 1999; MISRA et al., 2001; TONUI et 
al., 2004). Montanide ISA 720 (MISA 720) has been recommended by 
the manufacturer for clinical trials in humans (GOMEZ et al., 1999). 
This adjuvant has been used in malaria, HIV and cancer vaccine trials 
(KENNEY & EDELMAN, 2003) and has showed good responses 
(MYRIAM et al., 2005; OLIVEIRA et al., 2005; COLLINS et al., 2006). 
Montanide ISA 720 adjuvant combined with recombinant histone-1 
antigen was demonstrated to generate a durable cellular response that 
was sufficient to control infection in the majority of immunized Vervet 
monkeys (MASINA et al., 2003). However, despite the promising results, 
studies on Montanide ISA 720 as a potential adjuvant for Leishmania 
vaccines are very limited. The use of Bacille Calmette-Guerin (BCG) 
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as an adjuvant is regarded as an acceptable practice in humans, and at 
present this adjuvant is routinely used in vaccination and immunotherapy 
trials against leishmaniasis (CONVIT et al., 1989; BAHAR et al., 
1996; SHARIFI et al., 1998; MOMENI et al., 1999; KHALIL et al., 
2000). Despite the availability of numerous studies on development 
and evaluation of candidate vaccines against leishmaniasis, very limited 
data is available on the use of formalin-killed promastigotes in these 
studies. Most studies have focused on the use of autoclaved L. major 
promastigotes with or without adjuvants. It is of common knowledge 
that heat (autoclaving) denatures protein and this may interfere with 
the appropriate conformational structure of important antigen epitopes 
resulting in less efficacious vaccines. This study reports a new protocol 
that utilizes the subcutaneous route of immunization with formalin-killed 
promastigotes with alum, BCG or Montanide ISA 720 as adjuvants in a 
vaccine against murine cutaneous leishmaniasis.
MATERIALS AND METHODS
Mice and parasites: Female BALB/c mice, 6-8 weeks old, were 
obtained from the breeding stock and maintained in the same rodent 
facility of the Institute of Primate Research (IPR) throughout the 
experimental period. The L. major strain, NLB-144, originally isolated 
from Phlebotomus duboscqui in Baringo District, Kenya, and kept in 
a virulent state by continuous passage in BALB/c mice, was used in 
this study. An aspirate from the foot of an infected BALB/c mouse 
was cultured in complete M199 medium (Sigma, St. Louis, Missouri) 
and incubated at 25 ºC. Stationary phase promastigotes were harvested 
by centrifugation at 2500 rpm for 15 minutes at room temperature. 
The resulting pellet was washed three times by centrifugation in 
sterile Phosphate Buffered Saline (PBS) and then enumerated in a 
haemocytometer before the parasites were used.
Preparation of soluble Leishmania antigen (SLA): Antigen was 
prepared following the method described (GICHERU et al., 1995). 
Promastigotes were washed briefly and sonicated at 20 kHz for four 
periods of 40 seconds each on ice, separated by intervals of one minute. 
The sonicated material was rapidly frozen and thawed three times in 
liquid nitrogen for extraction of whole soluble protein. The parasite 
suspension was centrifuged at 10,000g for 30 minutes at 4 °C. The protein 
concentration from the supernatant was determined using the Bio Rad 
protein assay kit (Bio Rad) and stored at -70 °C until use. This antigen 
was used for coating ELISA plates for antibody assay.
Preparation of formalin-killed Leishmania major antigens: 
Leishmania major promastigotes used for immunization were harvested 
at stationary phase and washed three times in sterile PBS as described 
previously. Parasites were killed by suspension in 0.1% formalin 
overnight and then washed three times in PBS. The dead promastigotes 
were counted by haemocytometer and resuspended in a concentration 
of 5 x 108/mL in sterile PBS and stored at -70 ºC until required. The 
criteria for the determination of promastigote death were the absence of 
parasite motility and failure of parasites to grow in vitro when inoculated 
into culture medium.
Adjuvants: Montanide ISA 720 (Seppic France), kindly provided 
by Dr. Nicolas Fasel of Lausanne University, Switzerland, alum and 
Bacille Calmette-Guerin (BCG; Pasteur Institute of Iran) were used as 
adjuvants along with formalin-killed Leishmania major promastigotes.
Immunization: Five groups of twelve male BALB/c mice were 
immunized as follows: Group 1 received alum plus Leishmania major 
formalin-killed promastigotes (FKP), group 2 received BCG plus FKP, 
group 3 was injected with FKP alone, group 4 received Montanide ISA 
720 adjuvant (MISA) plus FKP and group 5 was injected with phosphate 
buffered saline (PBS) only and served as the negative control group. 
Two booster vaccinations of the same vaccine components and amount 
were given at four and six weeks following the initial vaccination. In all 
the vaccinated groups the amount of FKP per vaccine dose was 1 x 107. 
All the vaccines were reconstituted in PBS and given subcutaneously at 
the tailbase with a syringe and needle. The adjuvant dosages were 1 mg 
alum, 10 µL and 50 µL of Montanide ISA 720. In total, 300 µL of vaccine 
(promastigotes plus adjuvant) were injected to each experimental mouse. 
Two weeks after the third vaccination, mice from each group were either 
euthanized for the purpose of immunological assays or challenged with 
1 x 106 virulent L. major parasites for vaccine efficacy assessment. The 
Institutional Animal Care and Use and Scientific Review committees 
of the Institute of Primate Research approved this experiment. All mice 
experiments were performed in a biocontainment facility.
Infection of immunized and control mice: Two weeks after the 
third vaccination six mice from each group were challenged with virulent 
L. major promastigotes. Stationary phase promastigotes were prepared as 
described previously and counted. The right hind footpad was swabbed 
with 70% alcohol and allowed to dry as described (MACHARIA et al., 
2004). The footpad was infected by subcutaneously inoculating 50 µL 
of PBS containing 1 x 106 promastigotes. The thickness of the infected 
footpads was measured weekly for eight weeks using vernier caliper. 
Increase in footpad thickness was expressed as the difference between 
infected and the same noninfected footpad as described (SOLBACH et 
al., 1986).
Footpad parasitic load: To evaluate the relative efficacy of these 
vaccination protocols, challenged mice were euthanized and infected 
footpads removed between the ankle joint and toes and then homogenized 
with a tissue grinder in 3 mL of complete Schneider’s Drosophila insect 
tissue medium. Under sterile conditions, serial dilutions including 0.5 
mL (neat), 0.5 mL (1:2), 0.25 mL (1:4) and 0.125 mL (1:8) of the tissue 
homogenate were prepared in a total volume of 0.5 mL/well in wells 
of 48-well culture plates and incubated at 25 °C. Stationary phase (six 
days of incubation) parasites were counted by hemocytometer under a 
microscope and the total number of parasites in the original homogenate 
calculated using parasite counts in each dilution. The one-in-four dilutions 
were selected as the best dilution for the microtitration assay for data 
analysis. 
T cell proliferation assay: Splenic cells were harvested aseptically 
and purified with percoll gradients (Sigma, St. Louis, Missouri) to 
obtain splenic lymphocytes (PBL). The cells were adjusted to 3 x 106/
mL in complete RPMI-1640 (RPMI-1640 supplemented with 10% heat 
inactivated fetal bovine serum (Flow Laboratories, Irvin, UK) 2mM 
L-glutamine and 100 µg/mL gentamicin (Sigma) medium. One hundred 
microliters containing 3x106 cells/mL PBL in complete RPMI-1640 
were distributed to each well of a 96-well round-bottomed microtiter 
plate (Nunc, Rosklide, Denmark) followed by the addition of 100 µL 
of formalin-fixed L. major antigens (5 x 106 /mL) or concanavalin A 
(con A; 10 µg/mL; Sigma). Control wells received 100 µL of complete 
RPMI 1640 medium. Cultures were set up in duplicates and incubated 
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at 37 ºC in a humidified atmosphere containing 5% CO2 for five days for 
Leishmania antigen cultures and for three days for con A cultures. The 
cells were pulsed with 0.5µci of [Methyl-3H] thymidine (New England, 
Nuclear Boston, Massachusetts; 1.85 mBg/mL) over 18 hours and 
harvested on fibre glass filters (Titertek, Microtitration Equipment, UK). 
Incorporation of the radionuclide into DNA was determined by liquid 
scintillation spectrometry. Results were expressed as the stimulation 
index (SI) obtained by dividing the counts per minute of antigen or Con 
A by the counts per minute of the control cultures.
Determination of cytokines: Interferon gamma (IFN-γ) level was 
measured by enzyme-linked immunosorbent assay (ELISA). Purified 
splenic lymphocytes were adjusted to 3 x 106 cells/mL in complete 
RPMI 1640 medium and stimulated in vitro with either Con A or L. 
major antigens as described (OLOBO et al., 1992). Culture supernatants 
pooled from triplicate wells after 72 hours of stimulation were used 
to determine IFN-γ using mouse IFN-γ ELISA kit (Mabtech, AB, 
Sweden, Code 3321-1H-6) according to the manufacturer’s instructions. 
Polystyrene micro-ELISA plates (Nunc, Copenhagen, Denmark) were 
coated overnight with 100 µL of monoclonal antibody, AN18 (1 µg/mL) 
to capture IFN-γ from supernatants of samples and recombinant mouse 
IFN-γ standard. Nonspecific binding sites were blocked with 3% bovine 
serum albumin (BSA) in PBS for one hour at room temperature. The plate 
was washed six times with washing buffer before the addition of 100 µL 
of supernatant samples or mouse IFN-γ standards and incubation for two 
hours at room temperature. One hundred micro liters of monoclonal IFN-γ 
detecting antibody, R4-6A2-biotin (0.5 µg/mL) were added per well and 
the plate incubated for one hour at room temperature. Streptavidin-HRP 
was added to the wells at a dilution of 1:1000 and the plate incubated 
for one hour at room temperature before the addition of 100 µL/well 
of Tetramethlebenzidine (TMB) microwell peroxidase substrate (KPL, 
Maryland). Optical densities were read at 630 nm in a micro-plate reader 
(Dynatech Laboratories, UK).
Measurement of Leishmania-specific antibody responses: 
The assay was performed as described (GICHERU et al., 1995). 
Polystyrene Micro-ELISA plates (Nunc, Copenhagen, Denmark) were 
coated overnight with 100 µL of Leishmania major soluble antigen at a 
concentration of 10 µg/mL, diluted in carbonate-bicarbonate buffer (pH 
9.6). Nonspecific binding sites were blocked with 3% bovine serum 
albumin (BSA) in 0.01 M PBS (pH 7.2) for one hour at 37 °C. The 
plate was washed six times with washing buffer before the addition of 
100 µL of the serum samples and incubation for two hours at 37°C. The 
plate was washed six times as above and 100 µL of 1:4000 horse radish-
conjugated sheep anti-mouse IgG (Rockland Immunochemicals) was 
used as detecting antibody. Tetramethlebenzidine microwell peroxidase 
substrate (KPL, Maryland) was added to the wells and the plate incubated 
in the absence of light for 20 minutes before the optical densities were 
read at 630 nm in a micro-plate reader (Dynatech Laboratories, UK). 
All sera were tested at a dilution of 1:100 and the optical densities for 
different groups compared.
Statistical analysis: The differences in the levels of immune 
responses and protection were determined by one way ANOVA, 
Spearman’s rank correlation and the Tukey-Kramer test. Differences 
were considered significant when p < 0.05.
RESULTS
Antileishmanial antibodies: All vaccinated animals were clearly 
shown to be sero-positive when compared to the unvaccinated controls 
as indicated by the ELISA results. There was a significant difference in 
the production of L. major specific IgG between all the experimental and 
the negative control group with antibody responses being comparable and 
higher in the BCG-FKP and alum-FKP groups as compared to the MISA 
720 vaccinated group (p < 0.001). The MISA-FKP and the FKP-alone 
vaccinated groups showed similar IgG responses (Table 1).
Lymphoproliferative responses: All the animals responded to 
Con A with minimal variation. There was no significant difference in 
response to Con A between the vaccinated and control animals indicating 
the viability of the cells used. The ability of splenic lymphocytes to 
respond in vitro to the FKP antigen was significantly higher for the three 
adjuvant-FKP vaccinated groups than for the FKP vaccinated group (p 
< 0.001). The MISA-FKP vaccinated group showed significantly higher 
antigen-specific lymphoproliferative responses as compared to both the 
alum-KLM (p < 0.01) and the BCG-FKP (p < 0.001) vaccinated groups. 
Responses in BCG-KLM and alum-FKP were similar (Table 1).
Interferon-γ in cell supernatants: Cell culture supernatants 
collected from Con A in vitro stimulation for all the groups showed no 
difference in their IFN-γ response (Table 1). Antigen stimulated culture 
Table 1
Comparative immune responses and parasite loads in vaccinated and control BALB/c mice
Vaccination group IgG (OD)* Proliferation (SI)* IFN-γ (ng/mL)* Parasite load†
Ag Con A Ag Con A
Alum-FKP 0.359±0.017 60.3±2.6 111.6±11.649 27.48±0.79 146.6±1.202 234±41.67
BCG-FKP 0.405±0.041 58.2±0.7 118.4±5.367 82.48±0.53 148.2±2.465 34.7±6.23
Ag(FKP) 0.260±0.01 26.1±2.8 127.0±7.297 9.35±0.73 140.8±4.338 729±109.3
MISA-FKP 0.208±0.003 72.6±1.6 124.3±4.102 56.0±1.64 143.1±2.24 36.2±5.46
Control 0.093±0.015 4.35±1.04 109.7±14.065 0.68±0.063 139.4±3.858 1074±181.08
Data shown are the mean value per vaccination group ± SE (Standard Error). OD: Optical density; SI: Stimulation index; Ag: Antigen (FKP); Con A: Concanavalin A; 
ng/mL-nanograms per milliliter. * n = 6 (Alum-FKP, MISA-FKP and Control) and n = 5 (BCG-FKP and Ag (FKP); †Values x 104; n = 6 (MISA-FKP and Ag (FKP) 
and n = 5 (Alum-FKP, BCG-FKP and Control).
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supernatants from the vaccinated groups produced significantly higher 
levels of IFN-γ as compared to supernatants from the unvaccinated 
(negative control) group of mice. As compared to the FKP-alone 
vaccinated group, the adjuvant-FKP vaccinated groups produced 
significantly higher IFN-γ responses following stimulation with the 
FKP antigen (p < 0.0001). The BCG-FKP vaccinated mice produced 
IFN-γ responses that were significantly higher than that produced by the 
MISA-FKP vaccinated group (p < 0.001; Table 1) while IFN-γ responses 
induced by the MISA-FKP vaccinated animals were significantly higher 
than the levels produced by the alum-FKP vaccinated group (p < 0.001). 
Among the three adjuvants the BCG-FKP vaccinated mice produced the 
highest IFN-γ levels, followed by the MISA-FKP group with the alum-
FKP recording the least quantities of the cytokine.
Parasite burden in footpads of mice after challenge: Significantly 
lower levels of parasite numbers were obtained from the vaccinated 
groups of mice as compared to the negative control animals. Similarly, 
the parasite loads were found to be significantly lower for all the adjuvant-
FKP vaccinated groups when compared with the FKP group (Table 
1). The BCG-FKP and MISA 720-FKP vaccinated groups showed no 
significant difference in parasite numbers with both groups recording 
significantly lower parasite numbers when compared to all the other 
groups (p < 0.001). Spearman’s rank analysis of the mean parasite 
numbers and IFN-γ in the corresponding experimental and control groups 
indicated significant correlation between the two parameters. 
Lesion measurements in Leishmania major challenged mice: There 
was delayed lesion development in the MISA-FKP vaccinated group at least 
up to the third week post-challenge when the sizes of the footpads of mice 
in this group gradually started to increase (Fig. 1). This group maintained 
the lowest footpad sizes throughout the experimental period. The BCG-FKP 
vaccinated group, unexpectedly, developed higher lesion sizes as compared 
to all the other vaccinated groups up to the seventh week when the lesion 
sizes in this group gradually reduced to lower levels when compared only 
to the FKP antigen group among the vaccinated mice. The alum-FKP and 
FKP groups showed intermediate lesion development between the BCG-
FKP and MISA-FKP at least up to the seventh week post challenge when 
the FKP vaccinated group showed slightly elevated footpad swellings 
as compared to all the adjuvant-FKP vaccinated groups. The negative 
control group showed immediate response to the challenge infection by 
developing thicker footpads, which increased by 1.2 mm by the end of the 
first week post infection (Fig. 1). Eight weeks post challenge, the footpad 
thickness of the negative control mice had increased by an average of 3.5 
mm, leading to marked swelling of the infected footpad. Spearman’s rank 
correlation analysis showed no significant correlation between the mean 
lesion sizes measured at eight weeks post challenge and the mean IFN-γ 
of the corresponding vaccinated groups.
DISCUSSION
Results of the experiments described in this report demonstrate that 
injection of formalin-killed promastigotes with BCG induced the highest 
levels of antibody responses as compared with other adjuvants. This 
was not unexpected as BCG has been shown to be a strong stimulant 
of both cellular and humoral responses (SOHRABI et al., 2005). It was 
interesting to note that high antibody responses were accompanied by 
large cutaneous lesions. This is consistent with data that antibodies do not 
play a prominent role in protective immunity in leishmaniasis (OLOBO 
et al., 1980; HOWARD et al., 1984; GICHERU et al., 1995). Similarly to 
the BCG-FKP, vaccination using alum combined with FKP induced high 
antibody responses confirming previous findings that, alum-adjuvanted 
vaccines induce high and prolonged antibody responses (MISRA et al., 
2001; EICKHOFF & MAYERS, 2002). Montanide ISA 720 with FKP 
failed to increase the antibody responses to the antigen. These results 
differ from earlier findings in which peak antibody responses and 
persistence of parasite-specific antibody following human vaccination 
with Montanide ISA 720 formulated with Plasmodium falciparum antigen 
were comparable to those obtained following immunization with the same 
antigen mixed with alum (OLIVEIRA et al., 2005). 
 Parasite specific recall lymphocyte proliferation was demonstrated 
in all of the experimental groups. Marked Con A stimulation was 
demonstrated in all of the animals and there was no significant difference 
in response to Con A in both the experimental and control animals, 
indicating that the cells used were viable and active. The adjuvants 
used here were able to immunopotentiate the FKP as all the adjuvant-
FKP vaccinated groups had higher antigen specific recall proliferative 
responses when compared to the group vaccinated with FKP alone. Cells 
taken from mice vaccinated with MISA-FKP proliferated more when 
stimulated in vitro with formalin-fixed L. major promastigotes than 
cells taken from mice vaccinated with either alum-FKP or BCG-FKP. 
Our previous experience of the MISA 720 adjuvant + killed L. major 
vaccine in mice using the intraperitoneal route also gave the highest recall 
lympho-proliferative response than other adjuvants combined with the 
same antigen. This may indicate that Montanide ISA 720 adjuvant is 
more potent in immunopotentiating FKP in priming lymphocytes than 
both alum and BCG adjuvants.
 
Leishmania major studies in Vervet monkeys established that 
high levels of IFN-γ are produced in self cured animals (OLOBO et 
Fig. 1 - Lesion measurements in BALB/c mice following immunization and challenge 
with 1 x 106 virulent L. major promastigotes. Prior to challenge mice had been vaccinated 
subcutaneously with either alum-FKP, BCG-FKP, FKP alone, or MISA-FKP three times 
at weeks 0, 4 and 6. Control mice had been given phosphate buffered saline only. Animals 
were challenged two weeks after the last vaccination. Following challenge, the mice were 
monitored every week for eight weeks by measurement of lesion sizes using vernier caliper. 
The mean lesion size ± SE is shown. n = 6 (MISA–FKP and FKP each) and n = 5 (Alum-
FKP, BCG-FKP and control each).
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al., 1992). In the murine model of L. major infection it is now well 
established that protection depends on a cell-mediated immune response 
with expansion of a Th 1 subset of lymphocytes (LIEW et al., 1989; 
MOLL & MARTIN, 1990; SYPEK et al., 1993). The results of the 
current study clearly showed that high levels of IFN-γ were obtained 
in the BCG-FKP and MISA-FKP vaccinated groups of mice, with the 
BCG-FKP group producing significantly higher levels of the cytokine 
than the MISA-FKP group. Vaccination of mice with alum-FKP failed 
to produce protective levels of IFN-γ responses. This differs with 
previous studies where autoclaved L. major-alum vaccines have been 
shown to produce significant levels of IFN-γ and have been shown 
to be effective in treating persistent kala-azar dermal leishmaniasis 
(PKDL; MUSA et al,. 2008), although this may be an effect of the 
route of vaccination: intramuscular versus intra-dermal. However, the 
use of alum in combination with another adjuvant such as the BCG has 
contributed more to the high effectiveness of such vaccines (MISRA 
et al., 2001; KAMIL et al., 2003).
The good correlation obtained between the parasite burden and 
IFN-γ responses is an indication that resistance against L. major can 
only be achieved in vaccination protocols inducing high levels of IFN-γ. 
However, although BCG appears to be a better adjuvant as shown 
by the significantly higher IFN-γ responses in mice vaccinated with 
this adjuvant, it may lead to inflammatory reaction (SMRKOVSKI & 
LARSON, 1977; ALIMOHAMMADIAN et al., 2002) as evidenced by 
the largest cutaneous lesions recorded in the BCG group when compared 
to all other vaccinated groups. This may be the cause of failure to conclude 
significant correlation between the IFN-γ responses and lesion sizes. 
For this reason, the use of BCG as an adjuvant in vaccines needs to be 
discouraged. It would be equally important to discourage the use of lesion 
sizes as a parameter of evaluating vaccine efficacy in mice. 
 Another concern may be the route of immunization. In a previous 
study using the intraperitoneal route (data not shown), the outcome on 
the lesion size was better as compared to data on the present study. It is 
interesting to note that the subcutaneous route shows significantly reduced 
parasite numbers in both the BCG-FKP and MISA-FKP when these groups 
are compared with data obtained from the intraperitoneal immunization 
with BCG-FKP and MISA-FKP respectively. In conclusion, Montanide 
ISA 720 adjuvant appears to be the most appropriate for Leishmania 
vaccines due to its safety and ability to induce protective Th 1 responses 
when given by the subcutaneous route. It would be important to carry 
out further investigations on the potential use of Montanide ISA 720 
as an adjuvant for Leishmania vaccine in non-human primate models. 
Such studies would give a guide in designing vaccination protocols for 
clinical trials in humans.
RESUMO
Imunização subcutânea na infecção do camundongo pela 
Leishmania major: eficácia dos promastigotos mortos pela 
formalina combinada com adjuvantes
Promastigotos mortos pela formalina (FKP) de Leishmania major 
combinados com Montanide ISA 720 (MISA), BCG ou alumen foram 
usados na vacinação de modelo murino cutâneo de leishmaniose 
(CL). Aumento significante e específico de resposta IgG anti FKP 
foram detectados tanto no FKP com alumen como naquele com 
BCG comparados ao MISA-FKP (p < 0,001). Aumento significante 
da proliferação esplênica de linfócitos de memória foi obtida nos 
camundongos vacinados com MISA-FKP quando comparados aos 
grupos vacinados com alumen-FKP ou BCG-FKP (p < 0,01). As maiores 
respostas por interferon-gama foram observadas no grupo BCG-FKP 
seguido pelo MISA-FKP enquanto que o alumen-FKP deu a menor 
resposta. No grupo MISA-FKP foram obtidas reduções significantes do 
tamanho das lesões quando comparado aos grupos vacinados com BCG/
adjuvante de alumen-FKP. Embora o grupo BCG-FKP tenha mostrado 
a maior resposta por interferon-gama, não houve controle das lesões 
cutâneas. Redução significante no número de parasitas foi observada 
tanto no grupo vacinado com MISA-FKP como no BCG-FKP (p < 0,001). 
Houve boa correlação entre a carga parasitária e o nível de interferon-
gama indicando que a resposta do interferon-gama é parâmetro sensível 
do estado imunológico. Em conclusão, MISA-FKP é a forma mais eficaz 
de vacina contra a leishmaniose cutânea murina.
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